文献速递乳腺癌放疗放疗物理与技术

使用非专用直线加速器对早期乳腺癌进行术中放射治疗的长期结果

Long-Term Results of Intraoperative Radiation Therapy for Early Breast Cancer Using a Nondedicated Linear Accelerator.
PubMed 文献 · Adv Radiat Oncol · 2023-05-15

该研究纳入2004年至2019年接受非专用直线加速器术中放射治疗(21 Gy)的209例早期乳腺癌患者,中位随访145个月。5年、10年、15年总生存率分别为98%、94.7%、88%,15年局部无复发率为76%,共发生15例(7.2%)局部复发。作者认为术中放射治疗对选定病例可能仍是合理选择,但需更长随访。

要点

  • 209例早期乳腺癌患者接受非专用直线加速器术中放射治疗21 Gy,中位随访145个月。
  • 15年局部无复发率为76%,共发生15例(7.2%)局部复发。
  • 肿瘤>1 cm、III级和淋巴血管侵犯被确定为危险因素。

核心结论

  • 尽管约7%的复发率,作者认为术中放射治疗对选定病例可能仍是合理选择。
  • 作者指出这些患者需要更长随访,因为复发可能在10年后发生。

研究设计与样本

  • 研究纳入2004年至2019年随访≥1.5年的209例早期乳腺癌患者,中位年龄60.3岁(范围40-88.6)。
  • 纳入标准为活检证实的浸润性癌、年龄≥40岁、肿瘤大小≤3 cm、N0M0,排除多灶性病变和前哨淋巴结受累。
  • 所有患者术前接受乳腺磁共振成像,均行保乳手术加切缘评估和前哨淋巴结冰冻切片评估,若无切缘或前哨淋巴结受累则从手术室转运至直线加速器室行术中放射治疗(21 Gy)。

主要发现

  • 中位随访145个月(范围12.8-187.1),5年、10年、15年总生存率分别为98%、94.7%、88%。
  • 5年、10年、15年无病生存率分别为96.3%、90%、75.6%,15年局部无复发率为76%。
  • 随访期间共发生15例(7.2%)局部复发,局部复发平均时间为145个月(范围12.8-187.1)。
  • 作为首次事件,记录到3例淋巴结复发、3例远处转移和2例癌症相关死亡。
  • 肿瘤大小>1 cm、III级和淋巴血管侵犯被确定为危险因素。

关键数值与推荐

  • 术中放射治疗剂量为21 Gy。
  • pN0占90.5%(微转移7.2%,宏转移1.9%),切缘阴性占97%,淋巴血管侵犯率为10.6%。
  • 激素受体阴性12例,HER2阳性28例,Ki-67中位指数29%(范围0.1-85)。
  • 内在亚型分层:Luminal A型62.7%(n=131),Luminal B型19.1%(n=40),HER2富集型13.4%(n=28),三阴性4.8%(n=10)。

临床怎么用

  • 作者认为术中放射治疗对选定病例可能仍是合理选择。
  • 作者指出这些患者需要更长随访,因为复发可能在10年后发生。

局限性

  • 作者指出尽管约7%的复发率,术中放射治疗对选定病例可能仍是合理选择,但需要更长随访,因为复发可能在10年后发生。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To present the long-term results of intraoperative radiation therapy (IORT) for early breast cancer using a nondedicated linear accelerator. METHODS AND MATERIALS: The eligibility criteria were biopsy-proven invasive carcinoma, age ≥40 years, tumor size ≤3 cm, and N0M0. We excluded multifocal lesions and sentinel lymph node involvement. All patients had previously undergone breast magnetic resonance imaging. Breast-conserving surgery with margins and sentinel lymph node evaluation using frozen sections were performed in all cases. If there were no margins or involved sentinel lymph nodes, the patient was transferred from the operative suite to the linear accelerator room, where IORT was delivered (21 Gy). RESULTS: A total of 209 patients who were followed up for ≥1.5 years from 2004 to 2019 were included. The median age was 60.3 years (range, 40-88.6), and the mean pT was 1.3 cm (range, 0.2-4). There were 90.5% pN0 cases (7.2% of micrometastases and 1.9% of macrometastases). Ninety-seven percent of the cases were margin free. The rate of lymphovascular invasion was 10.6%. Twelve patients were negative for hormonal receptors, and 28 patients were HER2 positive. The median Ki-67 index was 29% (range, 0.1-85). Intrinsic subtype stratification was as follows: luminal A, 62.7% (n = 131); luminal B, 19.1% (n = 40); HER2 enriched 13.4% (n = 28); and triple negative, 4.8% (n = 10). Within the median follow-up of 145 months (range, 12.8-187.1), the 5-year, 10-year, and 15-year overall survival rates were 98%, 94.7%, and 88%, respectively. The 5-year, 10-year, and 15-year disease-free rates were 96.3%, 90%, and 75.6%, respectively. The 15-year local recurrence-free rate was 76%. Fifteen local recurrences (7.2%) occurred throughout the follow-up period. The mean time to local recurrence was 145 months (range, 12.8-187.1). As a first event, 3 cases of lymph node recurrence, 3 cases of distant metastasis, and 2 cancer-related deaths were recorded. Tumor size >1 cm, grade III, and lymphovascular invasion were identified as risk factors. CONCLUSIONS: Despite approximately 7% of recurrences, we may infer that IORT may still be a reasonable option for selected cases. However, these patients require a longer follow-up as recurrences may occur after 10 years.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Hanna SA, Bevilacqua JLB, de Barros ACSD, et al. Long-Term Results of Intraoperative Radiation Therapy for Early Breast Cancer Using a Nondedicated Linear Accelerator. Adv Radiat Oncol. 2023. PMID: 37408678. doi:10.1016/j.adro.2023.101233

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。